Advanced Search:
Equity Index Forex Crypto Commodity

VKTX - Viking Therapeutics

$68.62  -2.25 (-3.17%)

Updated: 03:14 May 5, 2024 EST

Next Hour's AI Forecast

96.82%

Avg. Accuracy (AI)

$77.04

Next Session's AI Forecast

97.37%

Avg. Accuracy (AI)

$80.33

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

$72.19

Viking Therapeutics's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

VIKING THERAPEUTICS - HISTORICAL DATA 6M

  • Last price

    $ 68.62

  • Daily change

    $ -2.25

  • Previous Close

    $ 70.87

  • Last Updated

    03:14 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.67 0.47 -0.16 0.92 0.13

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.67 2.52 4.9 4.44 3.77

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 76.7%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
79.24 7.43% 73.76 0.59% 73.33 82.73% 40.13

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.97 20 4.03 49.24

Viking Therapeutics Technical Analysis News

Viking Therapeutics

9920 Pacific Heights Boulevard
Suite 350
San Diego, CA 92121
United States
858 704 4660
https://www.vikingtherapeutics.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 28
Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Corporate Governance

Viking Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 8; Compensation: 8.

VIKING THERAPEUTICS'S HOLDERS RANK

List of holders with stock participation in Viking Therapeutics.

Holder Rank Holder Shares Date Reported % Out Value